[177Lu]Lu-FAP8-PEG3-IP-DOTA

N/A

Report date: 2025/10/23 16:05:39

NME

Base Information

Drug Name[177Lu]Lu-FAP8-PEG3-IP-DOTA

Drug Alias Name177Lu-FAP8-PEG3-IP-DOTA

ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionFibroblast activation protein alpha binders

TargetsProlyl endopeptidase FAP

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPurdue University

China Registration ClassN/A

Develop Information

Active CompaniesPurdue University

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A